A Genetic Key to Drug-Induced Uric Acid Changes
A recent study published in *The Pharmacogenomics Journal* investigates a potential pharmacogenomic interaction between the antipsychotic drug iloperidone and a specific genetic variant. The research focuses on the SLC2A9 gene variant rs7442295, exploring its association with baseline uric acid levels and its potential to modify the drug’s effect on this metabolic marker. This work represents a significant step in personalized medicine, moving beyond simple drug efficacy to understand how individual genetic makeup influences specific biochemical responses to medication, including potential adverse drug reactions.
Study Significance: For pharmacologists and clinicians, this finding underscores the critical role of pharmacogenomics in predicting and managing drug–drug interactions and metabolic side effects. It highlights the need to integrate genetic screening for variants like SLC2A9 into therapeutic drug monitoring protocols for medications affecting uric acid metabolism. This approach could refine dosing strategies and improve patient safety by identifying individuals at higher risk for specific adverse drug reactions before treatment begins.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
